Compare Robinhood Markets, Inc. (HOOD) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Robinhood Markets, Inc. vs Eli Lilly And Co — how do they compare? Robinhood Markets, Inc. trades at $109.02 (market cap $96.21B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 10.8× Robinhood Markets, Inc.'s market cap, and Eli Lilly And Co pays a 0.59% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Robinhood Markets, Inc. for 75 Days and Eli Lilly And Co for 93 Days on average.
| HOOD | LLY | |
|---|---|---|
Market Cap | $96.21B | $1.04T |
Volume | 22,572,153 | 3,064,878 |
Sector | Financials | Health |
52-Week High | $152.46 | $1.28K |
52-Week Low | $65.16 | $799.57 |
Typical Hold Time | 75 Days | 93 Days |
Enterprise Value | $102.75B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Robinhood (HOOD) trades at $107.01, down 2.28% today, amid a bullish technical setup with support at $105 and resistance at $109. The company reported strong 2025 results with revenue of $4.47 billion and net income of $1.88 billion, though Q1 2026 earnings missed expectations. Recent news highlights expansion into 24/7 stock trading and new product launches aimed at boosting engagement.
Outlook remains positive with a consensus price target of $137.53, implying 28% upside, supported by 77% analyst buy ratings. Key risks include high valuation multiples (P/E 47.35) and reliance on retail trading growth, while regulatory scrutiny and market volatility pose challenges to sustained momentum.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
